The changing spectrum of candidemia in oncology patients: Therapeutic implications

Current Opinion in Infectious Diseases

Volumn 13, Issue 6, 2000, Pages 615-620

  Marr, Kieren A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; GLYCOPEPTIDE; ITRACONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE; RAVUCONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; CANCER PATIENT; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PROPHYLAXIS; REVIEW; SOLID TUMOR; VIRULENCE;

EID: 0033673250     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200012000-00006     Document Type: Review

References (40)

1. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation
2. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
3. The epidemiology of hematogenous candidiasis caused by different Candida species
4. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
5. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans
6. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
7. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
8. Intestinal lesions associated with disseminated candidiasis in an experimental animal model
9. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750
10. Practice guidelines for the treatment of candidiasis
11. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
12. International surveillance of blood stream infections due to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
13. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
14. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: A prospective, randomized, double-blind study
15. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
16. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
17. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with hematological malignancies
18. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial
19. Antifungal prophylaxis in neutropenia
20. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North American and Latin American, 1997-1998
21. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
22. Importance of Candida species other than C. albicans as pathogens in oncology patients
23. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
24. Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole
25. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation
26. Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from Human Immunodeficiency Virus (HIV)-infected and non-HIV-infected individuals
27. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation
28. Rapid transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR
29. Isolation and characterization of fluconazole and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
30. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis
31. Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis
32. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
33. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis
34. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: Prevention and therapy
35. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
36. Liposomal amphotericin B for empiric therapy in patients with persistent fever and neutropenia
37. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
38. PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies
39. In vitro activity of the new echincandin antifungal, MK-0091, against common and uncommon clinical isolates of Candida species